These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 30450610)

  • 1. Model-Based Meta-Analysis in Ankylosing Spondylitis: A Quantitative Comparison of Biologics and Small Targeted Molecules.
    Wu Y; Feng X; Li J; Wang X; Yang C; Zhao L
    Clin Pharmacol Ther; 2019 May; 105(5):1244-1255. PubMed ID: 30450610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Propensity score matching/reweighting analysis comparing intravenous golimumab to infliximab for ankylosing spondylitis using data from the GO-ALIVE and ASSERT trials.
    Gensler LS; Chakravarty SD; Cameron C; Peterson S; Spin P; Kafka S; Nair S; Deodhar A
    Clin Rheumatol; 2020 Oct; 39(10):2907-2917. PubMed ID: 32367407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
    Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review and network meta-analysis of current and investigational treatments for active ankylosing spondylitis.
    Deodhar A; Chakravarty SD; Cameron C; Peterson S; Hensman R; Fogarty S; Spin P; Kafka S; Nair S; Gensler LS
    Clin Rheumatol; 2020 Aug; 39(8):2307-2315. PubMed ID: 32107666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
    Callhoff J; Sieper J; Weiß A; Zink A; Listing J
    Ann Rheum Dis; 2015 Jun; 74(6):1241-8. PubMed ID: 24718959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis.
    Baji P; Péntek M; Szántó S; Géher P; Gulácsi L; Balogh O; Brodszky V
    Eur J Health Econ; 2014 May; 15 Suppl 1(Suppl 1):S45-52. PubMed ID: 24832835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stability of fatigue, pain, patient global assessment and the Bath Ankylosing Spondylitis Functional Index (BASFI) in spondyloarthropathy patients with stable disease according to the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).
    Madsen OR
    Rheumatol Int; 2018 Mar; 38(3):425-432. PubMed ID: 29299630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in biologics for treating ankylosing spondylitis: the contribution of network meta-analysis.
    Migliore A; Gigliucci G; Integlia D; Isailovic N; Frediani B
    Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):56-64. PubMed ID: 33506892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study.
    Deodhar A; Reveille JD; Harrison DD; Kim L; Lo KH; Leu JH; Hsia EC
    J Rheumatol; 2018 Mar; 45(3):341-348. PubMed ID: 29247154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indirect comparison of the effects of anti-TNF biological agents in patients with ankylosing spondylitis by means of a mixed treatment comparison performed on efficacy data from published randomised, controlled trials.
    Migliore A; Broccoli S; Bizzi E; Laganà B
    J Med Econ; 2012; 15(3):473-80. PubMed ID: 22335398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintained clinical response of infliximab treatment in ankylosing spondylitis: a 6-year long-term study.
    Saougou I; Markatseli TE; Voulgari PV; Drosos AA
    Joint Bone Spine; 2010 Jul; 77(4):325-9. PubMed ID: 20452801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab: in ankylosing spondylitis.
    Robinson DM; Keating GM
    Drugs; 2005; 65(9):1283-91; discussion 1292-4. PubMed ID: 15916451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DOSAGE AND DURATION OF ETANERCEPT THERAPY FOR ANKYLOSING SPONDYLITIS: A META-ANALYSIS.
    Lee H; Jung Y; Song S; Lee J; Shim H; Kang W; Kim E
    Int J Technol Assess Health Care; 2017 Jan; 33(1):69-75. PubMed ID: 28434410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Secukinumab on Patient-Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1).
    Deodhar AA; Dougados M; Baeten DL; Cheng-Chung Wei J; Geusens P; Readie A; Richards HB; Martin R; Porter B
    Arthritis Rheumatol; 2016 Dec; 68(12):2901-2910. PubMed ID: 27390130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.
    Park W; Yoo DH; Jaworski J; Brzezicki J; Gnylorybov A; Kadinov V; Sariego IG; Abud-Mendoza C; Escalante WJ; Kang SW; Andersone D; Blanco F; Hong SS; Lee SH; Braun J
    Arthritis Res Ther; 2016 Jan; 18():25. PubMed ID: 26795209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic efficacy and safety of multiple intravenous infusions of infliximab in refractory ankylosing spondylitis patients with axial involvement.
    Rejón E; Giménez MD; Mayordomo L; Rodríguez S; González MP; Marenco JL
    Scand J Rheumatol; 2004; 33(5):323-6. PubMed ID: 15513681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study.
    Inman RD; Baraliakos X; Hermann KA; Braun J; Deodhar A; van der Heijde D; Xu S; Hsu B
    Arthritis Res Ther; 2016 Dec; 18(1):304. PubMed ID: 28031053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF-α Inhibitors for Up to 10 Years.
    Poddubnyy D; Fedorova A; Listing J; Haibel H; Baraliakos X; Braun J; Sieper J
    J Rheumatol; 2016 Dec; 43(12):2142-2148. PubMed ID: 27803139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs.
    Perrotta FM; Addimanda O; Ramonda R; D'Angelo S; Lubrano E; Marchesoni A; Olivieri I; Punzi L; Salvarani C; Spadaro A
    Reumatismo; 2014 Nov; 66(3):208-14. PubMed ID: 25376955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.